RecruitingNCT06763081

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation in Children and Youth (PGx-SImBA)

Sponsor

University of Manitoba

Enrollment

160 participants

Start Date

Mar 1, 2025

Study Type

OBSERVATIONAL

Conditions

Behavioral Activation Major Depressive Disorder Anxiety Disorders Antidepressant Drug Adverse Reaction Obsessive Compulsive Disorder (OCD)Major Depression

Summary

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Eligibility

Min Age: 6 YearsMax Age: 24 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating why some young people (ages 6–24) experience behavioral side effects — such as increased agitation, impulsivity, or unusual behavior — when taking SSRI antidepressants (like Prozac, Zoloft, or Lexapro) for depression, anxiety, or OCD. Researchers are looking for genetic factors that may predict who is at risk. **You may be eligible if...** - You are between 6 and 24 years old and live in Manitoba, Canada - You have been diagnosed with major depression, an anxiety disorder, or OCD - You have taken or are currently taking an SSRI antidepressant - (For cases) You experienced behavioral changes after starting an SSRI that went away when the dose was reduced or the drug was stopped - (For controls) You took an SSRI for at least 8 weeks with no side effects **You may NOT be eligible if...** - You have other conditions that might explain behavioral changes - You do not meet the age or diagnosis criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.